ACE-031 1mg

Within Europe this product is supplied including bacteriostatic water; outside Europe only the peptide vial is provided. For research use only – not for human or veterinary use.   Product Overview ACE-031 is a recombinant fusion protein studied for its role in signalling pathways associated with myostatin and related TGF-beta superfamily ligands. This 1 mg lyophilized research compound is designed for controlled laboratory investigation into muscle growth regulation, cellular signalling modulation and receptor–ligand interaction models.   Peptide Overview ACE-031 is based on a soluble activin type IIB receptor (ActRIIB) fusion construct. Metabolic and muscle-regulation research into myostatin signalling intensified between 2005 and 2015, leading to the development of receptor-based ligand traps for advanced pathway modelling. ACE-031 emerged as a reference compound within this research domain.   Historical Background and Scientific Context Research into myostatin as a negative regulator of skeletal muscle growth began in the late 1990s. By the early 2000s, the TGF-beta superfamily became a major focus in muscle-biology research. Between 2010 and 2025, ACE-031 has been used in laboratory settings to study receptor-mediated inhibition mechanisms, muscle hypertrophy models and downstream signalling cascades under controlled experimental conditions.   Structural & Molecular Characteristics • Molecular type: recombinant fusion protein • Functional domain: activin type IIB receptor fragment • Structural classification: ligand-binding receptor analogue • Typical molecular weight: approximately 110 kDa • Research focus: myostatin and TGF-beta ligand modulation   Mechanistic Focus in Research

• Myostatin and activin signalling pathway modelling
• Muscle growth and hypertrophy research models
• Ligand-receptor interaction studies
• TGF-beta superfamily signalling analysis
• Comparative evaluation of muscle-regulating compounds

  Analytical Verification (COA) Independent laboratory analysis performed by Liquilabs s.r.o. (Czechia) confirms full analytical validation for this batch. Testing confirms greater than 99.8 % purity, with assay content verified at 0.966 mg. Endotoxin levels were confirmed below 0.001 EU/mg. No detectable heavy metals were observed, including arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium. No microbial growth was detected. Identity was confirmed by chromatographic retention time and spectral validation.  

Grail Formula Quality

Every Grail Formula research peptide undergoes independent laboratory testing for purity, identity, structural integrity and microbial safety. All batches are verified for stability, low endotoxin levels and reproducibility to ensure reliable scientific outcomes.

When You Choose Grail Formula…

Researchers receive fully documented peptides with batch-number traceability, sealed-vial integrity and transparent laboratory verification. EU shipments include sterile bacteriostatic water; outside the EU only the peptide vial is supplied.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use

• Independently analysed by Liquilabs s.r.o. Czechia
• Greater than 99.8 % purity confirmed by COA
• Assay content verified at 0.966 mg
• Endotoxin level below 0.001 EU/mg
• No detectable heavy metals or microbial contamination
• Recombinant myostatin-pathway research compound
• EU shipments include bacteriostatic water
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.